Results 11 to 20 of about 8,134 (194)

Intravenous Tolvaptan Sodium Phosphate Can Fail to Improve Fluid Overload Due to Heart Failure in Patients With Chronic Kidney Disease: A Case Report. [PDF]

Pharmacol Res Perspect
ABSTRACT Tolvaptan is widely used as an adjunct oral diuretic to loop and thiazide diuretics for the management of fluid overload in patients with congestive heart failure. Recently, tolvaptan sodium phosphate (TSP), a water‐soluble prodrug of tolvaptan, was developed for intravenous administration and has demonstrated efficacy and safety in clinical ...
Uno T, Nakakura I, Ikeda A, Hosoda A, Mukai Y, Yamanishi K, Ohara N, Imanishi K, Une Y, Yokoyama S, Hosomi K.   +10 more
europepmc   +2 more sources

Real-World Effectiveness of Tolvaptan for Hyponatremia in Cirrhosis Across Global Regions: A Target Trial Emulation. [PDF]

JGH Open
ABSTRACT Background Tolvaptan promotes electrolyte‐free water excretion and is widely used in Asia for ascites, but in Western countries its use is limited to hyponatremia because of hepatotoxicity concerns. Methods We performed a retrospective cohort study using the TriNetX Research Network, emulating a target trial of cirrhotic patients with ...
Okushin K, Tateishi R, Fujishiro M, Tsutsumi T, Koike K, Tanaka T.   +5 more
europepmc   +2 more sources

Unexplained Hyponatremia Revealing Vitamin D Deficiency: A Clinical Case Report. [PDF]

Clin Case Rep
ABSTRACT “SIAD” (syndrome of inappropriate antidiuresis) is frequently encountered in clinical practice, often necessitating the exclusion of various differential diagnoses and involving expensive treatments. In cases of SIAD concomitant with vitamin D deficiency, treatment with vitamin D supplementation may not only correct hyponatremia but also ...
Yavuz Ileri S.
europepmc   +2 more sources

Syndrome of Inappropriate Secretion of Antidiuretic Hormone in a Dog With Meningoencephalitis of Unknown Etiology. [PDF]

Vet Med Sci
This report describes a case of syndrome of inappropriate antidiuretic hormone secretion (SIADH) in a Maltese with meningoencephalitis of unknown etiology (MUE). The dog was treated with water restriction and tolvaptan, a vasopressin receptor antagonist, which resulted in an improvement in hyponatremia.
Lee Y, Park J, Chae Y, Yun T, Kim H, Kang BT.   +5 more
europepmc   +2 more sources

The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis

Nefrología (English Edition), 2023
Background: The irreversible progression of autosomal dominant polycystic kidney disease (ADPKD) to end-stage renal disease (ESRD) is delayed by tolvaptan.
Xuanwei Li, Wenlai Li, Yue Li, Chuanjiang Dong, Ping Zhu   +4 more
doaj   +3 more sources

Tolvaptan response predictors in acute heart failure patients with congestion [PDF]

Pharmaceutical Sciences Asia, 2022
Tolvaptan has been used in many countries as an adjunct to diuretic therapy for heart failure. The identification of predictors of response to tolvaptan is essential in developing individual treatment plans, and this study therefore aims to identify ...
Hindun Wilda Risni, Rani Sauriasari, Oriza Satifa   +2 more
doaj   +1 more source

Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease [PDF]

, 2016
The neurohypophysial hormone arginine vasopressin (AVP) acts by three distinct receptor subtypes: V1a, V1b, and V2. In the liver, AVP is involved in ureogenesis, glycogenolysis, neoglucogenesis and regeneration. No data exist about the presence of AVP in
Alpini, Gianfranco, Carpino, Guido, Franchitto, Antonio, Gaudio, Eugenio, Glaser, Shannon, Mancinelli, Romina, Olivero, Francesca, Onori, Paolo, Pannarale, Luigi, Sferra, Roberta, Venter, Julie, Vetuschi, Antonella   +11 more
core   +1 more source

Tolvaptan

South Asian Journal of Cancer, 2014
AbstractHyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance. This drug review aims at discussing the currently approved oral vaptanagent Tolvaptan.
Bharath Rangarajan, Vineetha Binoy, Sachin Sharatchandra Hingmire, Vanita Noronha   +3 more
openaire   +3 more sources

UNDULY ENHANCED RESPONSE TO TOLVAPTAN IN A WOMAN SHOWING SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: AN INVESTIGATION OF POSSIBLE CAUSES [PDF]

, 2017
Objective: To investigate possible causes of an excessive response to tolvaptan in a woman with syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Lanzellotti, Davide, Martin, Marta, Padrini, Roberto, Panfili, Marco, Sartori, Geppo   +4 more
core   +1 more source

Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?

Kidney Diseases, 2021
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, accounting for approximately 5% of all ESRD cases worldwide.
Fei Liu, Chunyue Feng, Huijun Shen, Huaidong Fu, Jianhua Mao   +4 more
doaj   +1 more source